Drug
Teriflunomide clinical trials
Also written HMR1726 and Aubagio.
- studies test it
- 29
- open now
- 4
- in phase 3
- 9
- first study started
- 2001
Keep track of what changes. Save the teriflunomide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
- HMR1726
- 10
Studies by the year they started
29 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 12
- Phase 3
- 9
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 11
Sanofi (17) · Peking University People's Hospital (4) · Centre Hospitalier Universitaire de Nice (2) · Oslo University Hospital (1) · Genzyme, a Sanofi Company (1) · Providence Health & Services (1) · Jan Lycke (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
Often tested with
Tested in the same studies.
Cholestyramine Resin (3) · Charcoal (1) · Interferon beta-1a (1) · Glatiramer (1) · Colestipol (1)
Studies
Open first, then newest update. How each study uses teriflunomide is read from its arms, and is right about nine times in ten.
Testing it · 29
- Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic ParaparesisRecruitingPhase 1/2National Institute of Neurological Disorders and Stroke (NINDS)NCT04799288Written as Teriflunomide
- The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)RecruitingPhase 2Peking University People's HospitalNCT07065968Written as Teriflunomide
- Teriflunomide for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingPhase 2Peking University People's HospitalNCT06190145Written as Teriflunomide
- The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingPhase 2Peking University People's HospitalNCT06176911Written as Teriflunomide
- Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 WeeksCompletedPhase 4SanofiNCT04410965Written as TERIFLUNOMIDE
- Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune ThrombocytopeniaWithdrawnPhase 2Peking University People's HospitalNCT06176235Written as Teriflunomide
- Teriflunomide vs. Placebo During Gluten Challenge in Celiac DiseaseCompletedPhase 1/2Oslo University HospitalNCT04806737Written as Teriflunomide Oral Tablet
- Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisCompletedPhase 3Genzyme, a Sanofi CompanyNCT02201108Written as Teriflunomide
- To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisCompletedPhase 4SanofiNCT03856619Written as TERIFLUNOMIDE HMR1726
- A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension PeriodCompletedPhase 3Centre Hospitalier Universitaire de NiceNCT02587195Written as Teriflunomide
- Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated SyndromeCompletedPhase 3Centre Hospitalier Universitaire de NiceNCT03122652Written as Teriflunomide 14 MG Oral Tablet [Aubagio]
- MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCVCompletedPhase 4Providence Health & ServicesNCT01970410Written as teriflunomide
- Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple SclerosisCompletedPhase 4Jan LyckeNCT04129736Written as Teriflunomide 14 MG
- Rapid Elimination Procedure of Teriflunomide With Colestipol HydrochlorideTerminatedPhase 1Derrick Scott RobertsonNCT02263547Written as teriflunomide
- Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple SclerosisCompletedPhase 3SanofiNCT00622700Written as Teriflunomide
- Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple SclerosisCompletedPhase 3SanofiNCT00803049Written as Teriflunomide (HMR1726)
- Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsCompletedPhase 4SanofiNCT01895335Written as Teriflunomide
- An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple SclerosisCompletedPhase 3SanofiNCT00751881Written as Teriflunomide
- Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on TeriflunomideCompletedPhase 2SanofiNCT01403376Written as teriflunomide
- Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedPhase 2SanofiNCT00228163Written as teriflunomide (HMR1726)
See all 29 studies that test teriflunomide →
Given in every arm · 1 — teriflunomide is usual care beside what is tested
As the comparator · 17 — what is tested is compared with teriflunomide
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04586010Written as Teriflunomide
- Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT04586023Written as Teriflunomide
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05147220Written as Teriflunomide
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05156281Written as Teriflunomide
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.Active, not recruitingPhase 3SanofiNCT06372145Written as Teriflunomide
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisActive, not recruitingPhase 3SanofiNCT06141473Written as Teriflunomide
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)CompletedPhase 3SanofiNCT04410991Written as Teriflunomide HMR1726
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)CompletedPhase 3SanofiNCT04410978Written as Teriflunomide
- Study of Evobrutinib in Participants With RMS (evolutionRMS 1)TerminatedPhase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04338022Written as Teriflunomide
- Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisCompletedPhase 3ActelionNCT02425644Written as teriflunomide
- Study of Evobrutinib in Participants With RMS (evolutionRMS 2)TerminatedPhase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04338061Written as Teriflunomide
- Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple SclerosisCompletedPhase 2BiocadNCT04056897Written as Teriflunomide
- An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple SclerosisCompletedPhase 3BiocadNCT05385744Written as Teriflunomide
- Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)CompletedPhase 3TG Therapeutics, Inc.NCT03277248Written as Teriflunomide
- Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )CompletedPhase 3TG Therapeutics, Inc.NCT03277261Written as Teriflunomide
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.CompletedPhase 3Novartis PharmaceuticalsNCT02792231Written as Teriflunomide capsule
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisCompletedPhase 3Novartis PharmaceuticalsNCT02792218Written as Teriflunomide capsule
Codes
What other systems call teriflunomide · ClinicalTrials.gg INT005244
- MeSH (NLM) C527525teriflunomideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1C058IKG3BTERIFLUNOMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1310520Confirmed FDA, Wikidata
- Wikidata Q3077133teriflunomideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76662TeriflunomideOne source FDA
- DrugBank DB08880One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527525 | teriflunomide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1C058IKG3B | TERIFLUNOMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1310520 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3077133 | teriflunomide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76662 | Teriflunomide | One source FDA |
| DrugBank | DB08880 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.